TYRA insider transaction filings
Tyra Biosciences, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-17. Screen TYRA transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 5 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing by 1 insider — 972 shares, $20,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 4.
- Largest priced transaction: purchase of 972 shares @ $20.58 ($20,000) by Verjee Rehan, filed 2026-09-11.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Verjee Rehan — Director | 1 | 1 leg · 972 sh · $20,000 | — | — |
| Fuhrman Alan — Chief Financial Officer | 1 | — | — | 1 |
| Harris Todd — President and CEO, Director | 1 | — | — | 1 |
| RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner & RA Capital Healthcare Fund LP — Director, 10% owner & RA Capital Nexus Fund, L.P. — Director & Kolchinsky Peter — Director, 10% owner & Shah Rajeev M. — Director, 10% owner | 1 | — | — | 1 |
| Rueb Yuliya — Vice President, Finance (PAO) | 1 | — | — | 1 |
Recent Form 4 filings — Tyra Biosciences, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Harris Todd — President and CEO, Director | Grant/award (A): 864 @ $9.13 | EDGAR |
| 2026-09-17 | 4 | Fuhrman Alan — Chief Financial Officer | Grant/award (A): 951 @ $9.13 | EDGAR |
| 2026-09-17 | 4 | Rueb Yuliya — Vice President, Finance (PAO) | Grant/award (A): 2,925 @ $9.13 | EDGAR |
| 2026-09-17 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Purchase (P): 9,078,529 (derivative) @ $22.03 | EDGAR |
| 2026-09-11 | 4 | Verjee Rehan — Director | Purchase (P): 971.89 @ $20.58 | EDGAR |
| 2026-06-01 | 4 | Verjee Rehan — Director | Grant/award (A): 13,160 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Rothenberg Stephen Michael — Director | Grant/award (A): 13,160 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Simson Jake — Director | Grant/award (A): 13,160 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Moran Susan — Director | Grant/award (A): 13,160 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Gulfo Adele M. — Director | Grant/award (A): 13,160 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 13,160 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | MORE ROBERT J — Director | Grant/award (A): 13,160 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Warner Douglas J — Chief Medical Officer | Grant/award (A): 25,000 @ $0 · Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Rueb Yuliya — Vice President, Finance (PAO) | Grant/award (A): 8,333 @ $0 · Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Ashar Bhavesh — Chief Operating Officer | Grant/award (A): 15,013 @ $0 · Grant/award (A): 50,295 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Harris Todd — President and CEO, Director | Grant/award (A): 79,000 @ $0 · Grant/award (A): 265,000 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Fuhrman Alan — Chief Financial Officer | Grant/award (A): 20,000 @ $0 · Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Dable Habib J — Director | Grant/award (A): 44,400 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4 | KAPLAN GILLA — Director | Option exercise (M): 14,295 @ $2.25 · Sale (S): 14,295 @ $36.97 · Option exercise (M): 53,172 @ $2.25 · Disposition to issuer (D): 53,172 @ $37.75 · Option exercise (M): 14,295 (derivative) @ $0 · Option exercise (M): 53,172 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Harris Todd — President and CEO, Director | Grant/award (A): 1,463 @ $9.13 | EDGAR |
| 2026-03-17 | 4 | Fuhrman Alan — Chief Financial Officer | Grant/award (A): 1,376 @ $9.13 | EDGAR |
| 2026-02-13 | 4 | Bensen Daniel — Chief Discovery Officer | Sale (S): 2,128 @ $31.50 · Sale (S): 5,872 @ $33.37 | EDGAR |
| 2026-01-20 | 4 | Bensen Daniel — Chief Discovery Officer | Sale (S): 6,983 @ $28.44 · Sale (S): 1,017 @ $29.08 | EDGAR |
| 2025-12-19 | 4 | MORE ROBERT J — Director | Sale (S): 10,000 @ $25 | EDGAR |
| 2025-12-16 | 4 | Bensen Daniel — Chief Discovery Officer | Sale (S): 8,000 @ $22.64 | EDGAR |
| 2025-12-01 | 4 | Ashar Bhavesh — Chief Operating Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | MORE ROBERT J — Director | Sale (S): 246,871 @ $20.25 | EDGAR |
| 2025-11-19 | 4 | Bensen Daniel — Chief Operating Officer | Sale (S): 75,633 @ $16.07 · Sale (S): 49,956 @ $16.32 | EDGAR |
| 2025-11-17 | 4 | Bensen Daniel — Chief Operating Officer | Sale (S): 1,111 @ $16.00 · Sale (S): 110,228 @ $16.02 · Sale (S): 18,572 @ $16.11 · Sale (S): 1,500 @ $17.07 | EDGAR |
| 2025-09-17 | 4 | Fuhrman Alan — Chief Financial Officer | Grant/award (A): 701 @ $9.13 | EDGAR |
| 2025-08-07 | 4 | Bensen Daniel — Chief Operating Officer | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2025-08-07 | 4 | Warner Douglas J — Chief Medical Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-08-07 | 4 | Harris Todd — President and CEO, Director | Grant/award (A): 570,000 (derivative) @ $0 | EDGAR |
| 2025-08-07 | 4 | Fuhrman Alan — Chief Financial Officer | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | KAPLAN GILLA — Director | Sale (S): 10 @ $10.35 · Sale (S): 9,568 @ $9.78 | EDGAR |
| 2025-06-16 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Purchase (P): 31,307 @ $10.20 · Purchase (P): 120,167 @ $10.20 · Purchase (P): 11,813 @ $10.13 | EDGAR |
| 2025-06-16 | 4 | KAPLAN GILLA — Director | Sale (S): 30,000 @ $10.31 · Sale (S): 15,000 @ $10.31 · Sale (S): 6,814 @ $10.38 | EDGAR |
| 2025-06-11 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Purchase (P): 186,850 @ $10.19 | EDGAR |
| 2025-06-06 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Purchase (P): 997,864 @ $9.63 · Purchase (P): 213,334 @ $10.04 | EDGAR |
| 2025-06-02 | 4 | Verjee Rehan — Director | Grant/award (A): 22,200 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Rothenberg Stephen Michael — Director | Grant/award (A): 22,200 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Simson Jake — Director | Grant/award (A): 22,200 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Moran Susan — Director | Grant/award (A): 22,200 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 22,200 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | KAPLAN GILLA — Director | Grant/award (A): 22,200 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | MORE ROBERT J — Director | Grant/award (A): 22,200 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Harris Todd — President and CEO, Director | Grant/award (A): 1,241 @ $9.78 | EDGAR |
| 2025-03-18 | 4 | Fuhrman Alan — Chief Financial Officer | Grant/award (A): 1,238 @ $9.78 | EDGAR |
| 2025-02-07 | 4 | Kjellson Nina S — Director | Sale (S): 1,890 @ $13.76 · Sale (S): 3,511 @ $13.76 | EDGAR |
| 2025-01-31 | 4 | Gulfo Adele M. — Director | Grant/award (A): 37,200 (derivative) @ $0 | EDGAR |
Recent 8-K events — Tyra Biosciences, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-09 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-02 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-04-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-04 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-03-02 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TYRA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →